Jon Faldasz/LinkedIn
Nov 21, 2025, 08:55
Jon Faldasz: Why Aren’t We Better at Achieving Therapeutic Warfarin Control?
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Ok I know warfarin is the stinky kid in the corner, but it’s not going anywhere. So why aren’t we better at achieving time in therapeutic range?
Could it be:
– We think that 40% time in range is “good enough”? (data argues otherwise)
– Low warfarin use means we think this problem isn’t significant (patients would argue otherwise)
– We think that the problem is unsolvable? (Anticoagulation specialists argue otherwise)
I would love to get some comments to bring with me to the Anticoagulation Forum Stewardship Summit. Don’t make me call you out, people.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly